Pembrolizumab (Keytruda) for endometrial carcinoma – second line

March 2017
Technology Description:

Pembrolizumab is a new drug to treat endometrial carcinoma, which is a type of cancer that begins in the womb. The most common symptoms of this cancer are post-menopausal or irregular vaginal bleeding. Pembrolizumab is given straight into the bloodstream, and if licensed for use in the UK, it could improve survival in patients whose first treatment has stopped working.